A Proposal to Prevent the “Mephisto Sign” Side Effect of Botulinum Toxin Type A Injection in Chronic Migraine
4
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Botulinum toxin type A (BoNT-A) has been reported as an effective treatment for chronic migraine. When BoNT-A is injected on the frontalis muscle for chronic migraine, an unexpected clinical side effect called the “Mephisto sign” may occur. The aim of this article is to propose a method to eliminate or prevent the Mephisto sign side effect. A 25-year-old female patient visited the hospital and was diagnosed with chronic migraine. A total of 155 U of BoNT-A was injected into 31 sites. 2-weeks later, and the patient developed the Mephisto sign. An additional 2-U dose was administered bilaterally to the lateral-most point of the frontalis muscles, and the eyebrow morphology returned to normal within 2-3 weeks. We propose that the development of the Mephisto sign may be prevented with an additional BoNT-A injection of 2-4 U bilaterally to the lateral most point of the frontalis muscles during the primary injection process.
Abstract
Botulinum toxin type A (BoNT-A) has been reported as an effective treatment for chronic migraine. When BoNT-A is injected on the frontalis muscle for chronic migraine, an unexpected clinical side effect called the “Mephisto sign” may occur. The aim of this article is to propose a method to eliminate or prevent the Mephisto sign side effect. A 25-year-old female patient visited the hospital and was diagnosed with chronic migraine. A total of 155 U of BoNT-A was injected into 31 sites. 2-weeks later, and the patient developed the Mephisto sign. An additional 2-U dose was administered bilaterally to the lateral-most point of the frontalis muscles, and the eyebrow morphology returned to normal within 2-3 weeks. We propose that the development of the Mephisto sign may be prevented with an additional BoNT-A injection of 2-4 U bilaterally to the lateral most point of the frontalis muscles during the primary injection process.
참고문헌 (6)
- Aurora SK, "OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial", Cephalalgia, 30, pp.793~803 (2010)
- Diener HC, "OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial", Cephalalgia, 30, pp.804~814 (2010)
- Blumenfeld A, "Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program", Headache, 50, pp.1406~1418 (2010)
- De Maio M, "Safety of Botulinum Toxin in Aesthetic Medicine. In: Botulinum Toxin in Aesthetic Medicine", pp.123~ (2007), Springer-Verlag
- Carruthers A, "Horizontal forehead lines. In: Using Botulinum Toxins Cosmetically: a Practical Guide", pp.35~ (2003), Taylor & Francis Group
- Carruthers A, "Upper face treatment. In: Botulinum Toxin", pp.36~ (2005), Elsevier Saunders